CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 3.17: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.24%Below 5Y avg (0.51%)
Annual Rate
CNY 0.01Paid annual
Payout Ratio
13.8%Sustainable
Last Ex-Dividend
May 27, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.91BCNY434.93M · vs all stocks (USD)
Trailing P/E
54.56xRevenue (TTM)
790.94MCNY118.02M · vs all stocks (USD)
Profit Margin
6.93%Beta
0.1950xvs all stocks
52-Week Change
-9.91%vs all stocks
Market Capitalization
2.91BCNY434.93M · vs all stocks (USD)
Enterprise Value
2.91BCNY434.76M · vs all stocks (USD)
Trailing P/E
54.56xPrice to Sales (TTM)
3.69xPrice to Book (MRQ)
1.63xEnterprise to Revenue
3.68xEnterprise to EBITDA
19.78xGross Margin
20.21%Profit Margin
6.93%Operating Margin
6.07%Return on Assets (TTM)
1.18%Return on Equity (TTM)
3.17%Revenue (TTM)
790.94MCNY118.02M · vs all stocks (USD)
Revenue per Share (TTM)
1.34CNYUpdated Sep 20, 2026Quarterly Revenue Growth
23.80%Gross Profit (TTM)
155.35MCNY23.18M · vs all stocks (USD)
EBITDA (TTM)
87.50MCNY13.06M · vs all stocks (USD)
Net Income (TTM)
54.77MCNY8.17M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-1.20%Operating Cash Flow (TTM)
110.15MCNY16.44M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-40.76MCNY-6.08M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0120CNYUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.24%vs all stocks
5-Year Average Dividend Yield
0.51%vs all stocks
Payout Ratio
13.79%Revenue
745.31MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
571.24MCNYFY2025 · Dec 31, 2025Gross Profit
174.07MCNYFY2025 · Dec 31, 2025Operating Income
79.92MCNY11.93M · vs all stocks (USD)
Pre-tax Income
61.92MCNYFY2025 · Dec 31, 2025Income Tax Expense
7.58MCNYFY2025 · Dec 31, 2025Net Income
54.34MCNYFY2025 · Dec 31, 2025EBIT
65.93MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
179.57MCNYFY2025 · Dec 31, 2025Research & Development
25.48MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
17.64MCNYFY2025 · Dec 31, 2025Other Operating Expenses
12.32MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.78MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
4.01MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0928CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0868CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
585.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
585.53MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
54.34MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
1.90KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
70.21MCNYFY2025 · Dec 31, 2025Free Cash Flow
-8.91MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
458.77MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
54.34MCNYFY2025 · Dec 31, 2025Other Non-cash Items
3.91MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
71.76MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-59.79MCNYFY2025 · Dec 31, 2025Capital Expenditures
-79.12MCNYFY2025 · Dec 31, 2025Other Investing Activity
5.88MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-73.24MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
54.40MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-52.10MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-18.28MCNYFY2025 · Dec 31, 2025Other Financing Charges
-56.00MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-71.98MCNYFY2025 · Dec 31, 2025Shares Outstanding
593.62MSharesUpdated Sep 20, 2026Float Shares
382.32MSharesUpdated Sep 20, 2026% Held by Insiders
31.59%vs all stocks
% Held by Institutions
5.71%vs all stocks
Total Cash (MRQ)
453.40MCNY67.66M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.7780CNYUpdated Sep 20, 2026Total Debt (MRQ)
504.21MCNY75.24M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2875xCurrent Ratio (MRQ)
4.21xBook Value per Share (MRQ)
3.01CNYUpdated Sep 20, 2026Total Assets
2.55BCNY380.46M · vs all stocks (USD)
Total Current Assets
1.15BCNYFY2025 · Dec 31, 2025Total Liabilities
826.49MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.40BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
590.64MCNYFY2025 · Dec 31, 2025Total Current Liabilities
235.85MCNYFY2025 · Dec 31, 2025Cash
458.77MCNYFY2025 · Dec 31, 2025Cash Equivalents
23.61MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
482.38MCNYFY2025 · Dec 31, 2025Accounts Receivable
180.62MCNYFY2025 · Dec 31, 2025Inventory
401.37MCNYFY2025 · Dec 31, 2025Accounts Payable
152.18MCNYFY2025 · Dec 31, 2025Short-term Debt
6.49MCNYFY2025 · Dec 31, 2025Other Current Liabilities
38.15MCNYFY2025 · Dec 31, 2025Long-term Debt
493.70MCNYFY2025 · Dec 31, 2025Common Stock (Book)
593.61MCNYFY2025 · Dec 31, 2025Retained Earnings
448.91MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.72BCNY257.14M · vs all stocks (USD)
Treasury Stock
56.11MCNYFY2025 · Dec 31, 202552-Week Low
4.46CNYUpdated Sep 20, 202652-Week High
6.82CNYUpdated Sep 20, 202652-Week Change
-9.91%vs all stocks
Beta
0.1950xvs all stocks
50-Day MA
4.99CNYUpdated Sep 20, 2026200-Day MA
5.48CNYUpdated Sep 20, 2026Avg 10-Day Volume
6.00MSharesUpdated Sep 20, 2026Avg 30-Day Volume
8.24MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.0900CNYUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.17: safe zoneNotable
Altman Z-Score: 3.17
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Hangzhou Tianmu-Shan Pharmaceutical Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Kehua Bio-Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eikon Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
DiaMedica Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Clover Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Honz Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Prothena Corporation plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hua Medicine Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guanhao Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule